Pharvaris N.V. is a clinical-stage company dedicated to developing and commercializing oral drugs that target crucial biological pathways that are well-suited to address multiple indications. The company's primary focus is on the development of treatments for patients suffering from hereditary angioedema (HAE), a rare genetic disorder affecting roughly 1 in 10,000 to 1 in 50,000 people globally, which causes episodic yet severe swelling attacks.
Pharvaris was founded in 2015 and is registered in the Netherlands. The company deploys an innovative approach to drug development, leveraging its expertise in small molecule drug discovery and development, specifically focusing on Bruton’s tyrosine kinase (BTK) inhibitor design and synthesis. BTK plays a critical role in the onset of swelling in HAE patients, hence the significance of this line of research.
The company's lead program, PHVS416, utilizes this approach and is a technologically advanced oral formulation of PHA121, a potent and selective BTK inhibitor. PHVS416 is designed to provide effective, rapid, and sustained relief from HAE attacks, hence significantly improving the patients' quality of life. Similarly, Pharvaris is advancing another drug candidate, PHVS719, which is also an orally administered BTK inhibitor targeting HAE prophylaxis.
Pharvaris's commitment to developing oral therapies for HAE stems from the understanding that many patients prefer oral medication. Current treatments for HAE primarily involve intravenous or subcutaneous injections, which can be inconvenient and painful for patients. Aside from making treatments more patient-friendly, the development of orally administered drugs for HAE may also serve to expand the treatment market.
Pharvaris expressed its commitment to drug development for HAE treatment and other potential indications by pointing out that small molecule BTK inhibition, in addition to HAE, holds the potential for therapeutic benefit in a broad range of other diseases, and they are dedicated to exploring these possibilities.
Since its establishment, Pharvaris has equipped itself with a team of scientists possessing extensive experience in the pharmaceutical industry, particularly in the area of small molecule drug discovery and development. With a management team that holds a proven track record in the pharmaceutical industry, Pharvaris is well-positioned to fulfill its mission of developing and commercializing new treatments for patients with significant unmet medical needs.
To summarize, Pharvaris is striving to bring about a paradigm shift in the treatment options for hereditary angioedema and potentially other diseases. They continue to leverage their expertise, innovative approach, and dedication to patient-centric solutions to revolutionize care for HAE patients. As a relatively young company with a robust pipeline, Pharvaris is well-positioned for future growth.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pharvaris reported its Q3 2026 results, indicating €283 million in cash and cash equivalents. The company's deucrictibant IR new drug application is currently under FDA review with a PDUFA date set for April 23, 2027, and topline data for deucrictibant XR is expected in Q1 2027. Pharvaris continues to fund its operations primarily through equity sales and anticipates no revenue until 2027, pending FDA approval.
This Stock Traders Daily analysis for Pharvaris N.v. (NASDAQ: PHVS) suggests a strong overweight bias across all time horizons, identifying a mid-channel oscillation pattern. The report highlights an exceptional 40.3:1 risk-reward setup, targeting an 11.4% gain with only 0.3% risk. It provides specific institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Pharvaris N.V. (PHVS) has published a slide deck related to its presentation at the 2026 HAEi Regional Conference Americas. The content is provided by Seeking Alpha's transcripts team, which focuses on developing and publishing earnings call transcripts and other related projects.
Bank of America Securities upgraded Pharvaris N.V. (NASDAQ: PHVS) to Buy with a $44 price target, citing an attractive entry point after shares pulled back despite positive Phase 3 prophylaxis data. The company's lead drug, deucrictibant, is being developed in two oral formulations for hereditary angioedema (HAE) to offer both prophylactic and on-demand treatment, making Pharvaris the only company with oral options in both settings. The FDA is reviewing the on-demand formulation, with a decision expected by April 23, 2027, and the prophylaxis market is projected to reach $917 million in peak sales.
This article analyzes Pharvaris N.v. (PHVS) using AI models to provide insights into its near-term, mid-term, and long-term outlook. It identifies positive near-term sentiment but a potential for mid-term weakness within a long-term strength context. The analysis includes three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key support/resistance levels.